Skip to content
2000
Volume 5, Issue 1
  • ISSN: 3050-6115
  • E-ISSN: 3050-6123

Abstract

Objective

Ulcerative colitis (UC) and Crohn's disease (CD) are two forms of inflammatory bowel disease (IBD) and may be associated with the formation of urinary stones. Urinary lithiasis is a common condition that affects both men and women, and its prevalence is increasing due to dietary and environmental factors. Understanding the association between IBD and urolithiasis is important for the comprehensive treatment of patients. This review aims to evaluate the relationship between IBD and the formation of urinary calculi.

Methodology

PubMed/Medline database was used using the keywords simultaneously: (Inflammatory Bowel Disease) or (Crohn’s Disease) or (Ulcerative Colitis) and (Urolithiasis). After the preliminary search, 61 of 111 studies on the subject were examined. Other studies were included by the authors.

Results

Urinary lithiasis is more prevalent in patients with Inflammatory Bowel Disease. The latter can be described as a risk factor for the former.

Conclusion

Patients with IBD are at increased risk of developing urolithiasis. Despite the limitations of this study, these patients may benefit from early screening, as well as strict control of disease activity, diet, medication and behaviors.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cset/10.2174/0122102981375859250512064438
2025-05-27
2025-12-21

  • From This Site

    /content/journals/cset/10.2174/0122102981375859250512064438
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ganji-ArjenakiM. NasriH. Rafieian-KopaeiM. Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; A clinical review and meta-analysis.J. Nephropathol.20176326426910.15171/jnp.2017.4228975110
     [Google Scholar]
  2. LevineJ.S. BurakoffR. Extraintestinal manifestations of inflammatory bowel disease.Gastroenterol. Hepatol.20117423524121857821
     [Google Scholar]
  3. OikonomouK. KapsoritakisA. EleftheriadisT. StefanidisI. PotamianosS. Renal manifestations and complications of inflammatory bowel disease.Inflamm. Bowel Dis.20111741034104510.1002/ibd.2146820842645
     [Google Scholar]
  4. van HoeveK. HoffmanI. Renal manifestations in inflammatory bowel disease: A systematic review.J. Gastroenterol.202257961962910.1007/s00535‑022‑01903‑635834005
     [Google Scholar]
  5. HarbordM. AnneseV. VavrickaS.R. AllezM. Barreiro-de AcostaM. BobergK.M. BurischJ. De VosM. De VriesA.M. DickA.D. JuilleratP. KarlsenT.H. KoutroubakisI. LakatosP.L. OrchardT. PapayP. RaineT. ReinshagenM. ThaciD. TilgH. CarbonnelF. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease.J. Crohn’s Colitis201610323925410.1093/ecco‑jcc/jjv21326614685
     [Google Scholar]
  6. HueppelshaeuserR. von UnruhG.E. HabbigS. BeckB.B. BuderusS. HesseA. HoppeB. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn’s disease.Pediatr. Nephrol.20122771103110910.1007/s00467‑012‑2126‑822366809
     [Google Scholar]
  7. GascheC. Complications of inflammatory bowel disease.Hepatogastroenterology20004731495610690585
     [Google Scholar]
  8. ManganiotisA.N. BannerM.P. MalkowiczS.B. Urologic complications of Crohn’s disease.Surg. Clin. North Am.200181119721510.1016/S0039‑6109(05)70281‑4
     [Google Scholar]
  9. AdlerG. ReinshagenM. Extraintestinale manifestationen.Z. Gastroenterol.2003411546110.1055/s‑2003‑36670
     [Google Scholar]
  10. OefeleinM.G. Urologic manifestations of nonurologic diseases.Urol. Clin. North Am.2003301637210.1016/S0094‑0143(02)00110‑612580558
     [Google Scholar]
  11. YumuraY. OotaJ. FujikawaA. YokomizoY. MoriyamaM. The relationship between inflammatory bowel disease (IBD) and complications of urinary and male genital tracts.Hinyokika Kiyo20095511677683
     [Google Scholar]
  12. AwedewA.F. HanH. BericeB.N. DodgeM. SchneiderR.D. Abbasi-KangevariM. Al-AlyZ. AlmidaniO. AlvandS. ArablooJ. AravkinA.Y. AyanaT.M. BhardwajN. BhardwajP. BhaskarS. BikbovB. Caetano dos SantosF.L. CharanJ. Cruz-MartinsN. DadrasO. DaiX. DigesaL.E. ElhadiM. ElmonemM.A. EsezoborC.I. FatehizadehA. GebremeskelT.G. GetachewM.E. GhamariS-H. HayS.I. IlicI.M. IlicM.D. JayarajahU. JazayeriS.B. KimM.S. LeeS-W. LeeS.W.H. LimS.S. MahmoudM.A. MalikA.A. MentisA-F.A. MestrovicT. MichalekI.M. MihrtieG.N. MirrakhimovE.M. MokdadA.H. MoniM.A. MoradiM. MurrayC.J.L. OrtizA. PawarS. PericoN. RashidiM-M. RawassizadehR. RemuzziG. SchumacherA.E. SinghJ.A. SkryabinV.Y. SkryabinaA.A. TanK-K. TolaniM.A. Valadan TahbazS. ValizadehR. VoB. WoldeA.A. Yahyazadeh JabbariS.H. YazdanpanahF. YiğitA. YiğitV. ZahirM. ZastrozhinM. ZhangZ-J. ZumlaA. MisganawA. DiracM.A. The global, regional, and national burden of urolithiasis in 204 countries and territories, 2000–2021: A systematic analysis for the global burden of disease study 2021.EClinicalMedicine20247810292410.1016/j.eclinm.2024.102924
     [Google Scholar]
  13. WangR. LiZ. LiuS. ZhangD. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019.BMJ Open2023133e06518610.1136/bmjopen‑2022‑06518636977543
     [Google Scholar]
  14. Ben-AmiH. GinesinY. BeharD.M. FisherD. EdouteY. LavyA. Diagnosis and treatment of urinary tract complications in Crohn’s disease: An experience over 15 years.Can. J. Gastroenterol.200216422522910.1155/2002/20461411981574
     [Google Scholar]
  15. McConnellN. CampbellS. GillandersI. RoltonH. DaneshB. Risk factors for developing renal stones in inflammatory bowel disease.BJU Int.200289983584110.1046/j.1464‑410X.2002.02739.x12010224
     [Google Scholar]
  16. StarkC.M. GormanG.H. NylundC.M. Association of inflammatory bowel disease and urolithiasis in hospitalized pediatric patients.Inflamm. Bowel Dis.201723101777178210.1097/MIB.000000000000118828696957
     [Google Scholar]
  17. FagagniniS. HeinrichH. RosselJ.B. BiedermannL. FreiP. ZeitzJ. SpalingerM. BattegayE. ZimmerliL. VavrickaS.R. RoglerG. ScharlM. MisselwitzB. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases.PLoS One20171210e018519310.1371/journal.pone.018519329023532
     [Google Scholar]
  18. ScalesC.D. SmithA.C. HanleyJ.M. SaigalC.S. Prevalence of kidney stones in the United States.Eur. Urol.201262116016510.1016/j.eururo.2012.03.05222498635
     [Google Scholar]
  19. StamatelouK.K. FrancisM.E. JonesC.A. NybergL.M. CurhanG.C. Time trends in reported prevalence of kidney stones in the United States: 1976–1994.Kidney Int.20036351817182310.1046/j.1523‑1755.2003.00917.x12675858
     [Google Scholar]
  20. PearleM.S. CalhounE.A. CurhanG.C. Urologic diseases in America project.Urolithiasis. J. Urol.2005173384885710.1097/01.ju.0000152082.14384.d715711292
     [Google Scholar]
  21. CoricaD. RomanoC. Renal involvement in inflammatory bowel diseases.J. Crohn’s Colitis201610222623510.1093/ecco‑jcc/jjv13826223844
     [Google Scholar]
  22. ParksJ.H. WorcesterE.M. O’ConnorR.C. CoeF.L. Urine stone risk factors in nephrolithiasis patients with and without bowel disease.Kidney Int.200363125526510.1046/j.1523‑1755.2003.00725.x12472791
     [Google Scholar]
  23. KumarR. GhoshalU.C. SinghG. MittalR.D. Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: Possible role in renal stone formation.J. Gastroenterol. Hepatol.200419121403140910.1111/j.1440‑1746.2004.03510.x15610315
     [Google Scholar]
  24. KimM.J. WooS. KimE.R. HongS.N. ChangD.K. RheeP.L. KimJ.J. RheeJ.C. KimY.H. Incidence and risk factors for urolithiasis in patients with Crohn’s disease.Urol. Int.201595331431910.1159/00037553625895526
     [Google Scholar]
  25. DimkeH. Winther-JensenM. AllinK.H. LundL. JessT. Risk of urolithiasis in patients with inflammatory bowel disease: A nationwide danish cohort study 1977–2018.Clin. Gastroenterol. Hepatol.2021191225322540.e210.1016/j.cgh.2020.09.04933007511
     [Google Scholar]
  26. MakW.Y. ZhaoM. NgS.C. BurischJ. The epidemiology of inflammatory bowel disease: East meets west.J. Gastroenterol. Hepatol.202035338038910.1111/jgh.1487231596960
     [Google Scholar]
  27. CuryD. MossA. SchorN. Nephrolithiasis in patients with inflammatory bowel disease in the community.Int. J. Nephrol. Renovasc. Dis.2013613914210.2147/IJNRD.S4546623935383
     [Google Scholar]
  28. VianaM.L. PontesR.M. GarciaW.E. FáveroM.E. PreteD.C. MatsuoT. Crohn’s disease and kidney stones: much more than coincidence?Arq. Gastroenterol.200744321021410.1590/s0004‑28032007000300006
     [Google Scholar]
  29. BoussorraH. SallamiS. SaidY. ChebilM. NajjarT. Evaluation of urolithiasis in Crohn’s disease in Tunisian patients.Tunis. Med.201391744044324008874
     [Google Scholar]
  30. DincerM.T. DincerZ.T. BakkalogluO.K. YalinS.F. TrabulusS. CelikA.F. SeyahiN. AltiparmakM.R. Renal manifestations in inflammatory bowel disease: A cohort study during the biologic era.Med. Sci. Monit.202228e93649710.12659/MSM.93649735791280
     [Google Scholar]
  31. KumarS. PollokR. GoldsmithD. Renal and urological disorders associated with inflammatory bowel disease.Inflamm. Bowel Dis.2022izac14010.1093/ibd/izac14035942657
     [Google Scholar]
  32. TrinchieriA. LizzanoR. CastelnuovoC. ZanettiG. PisaniE. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease.Arch. Ital. Urol. Androl.2002742616412161938
     [Google Scholar]
  33. TorioM. IshimuraM. OhgaS. DoiT. UtsunomiyaR. OhkuboK. SugaN. TatsugamiK. MatsumotoT. TakadaH. HaraT. Nephrolithiasis as an extra-intestinal presentation of pediatric inflammatory bowel disease unclassified.J. Crohn’s Colitis20104667467810.1016/j.crohns.2010.05.01221122580
     [Google Scholar]
  34. JungD. AlshaikhA. RatakondaS. BashirM. AminR. JeonS. StevensJ. SharmaS. AhmedW. MuschM. HassanH. Adenosinergic signaling inhibits oxalate transport by human intestinal Caco2-BBE cells through the A2B adenosine receptor.Am. J. Physiol. Cell Physiol.20183155C687C69810.1152/ajpcell.00024.201730020825
     [Google Scholar]
  35. TorricelliF.C. ReichardC. MongaM. Urolithiasis in complicated inflammatory bowel disease: A comprehensive analysis of urine profile and stone composition.Int. Urol. Nephrol.202153220520910.1007/s11255‑020‑02649‑x32915375
     [Google Scholar]
  36. GkentzisA. KimuliM. CartledgeJ. TraxerO. BiyaniC.S. Urolithiasis in inflammatory bowel disease and bariatric surgery.World J. Nephrol.20165653854610.5527/wjn.v5.i6.53827872836
     [Google Scholar]
  37. AssimosD.G. Re: Urolithiasis in inflammatory bowel disease and bariatric surgery.J. Urol.2017198347847910.1016/j.juro.2017.06.02628817906
     [Google Scholar]
  38. MiyajimaS. IshiiT. WatanabeM. UekiT. TanakaM. Risk factors for urolithiasis in patients with Crohn’s disease.Int. J. Urol.202128222022410.1111/iju.1444233191551
     [Google Scholar]
  39. AroraZ. MukewarS. LopezR. CaminoD. ShenB. HallP. Etiopathogenesis of nephrolithiasis in ulcerative colitis patients with the ileal pouch anal anastomosis.Inflamm. Bowel Dis.201723584084610.1097/MIB.000000000000107028301430
     [Google Scholar]
  40. ShiY.J. Y.u, S.; Tian, B.W.; Dai, Y.M.; Xu, H.; Tan, B.; Li, Y. Risk factors and characteristics of gut microbiota and metabolites in inflammatory bowel diseases patients with urolithiasis.Zhonghua Yi Xue Za Zhi2022102443525353110.3760/cma.j.cn112137‑20220519‑01111
     [Google Scholar]
  41. de la VegaL.P. LieskeJ.C. MillinerD. GonyeaJ. KellyD.G. Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose.JPEN J. Parenter. Enteral Nutr.200428643543810.1177/014860710402800643515568291
     [Google Scholar]
  42. DurandoM. TiuH. KimJ.S. Sulfasalazine-induced crystalluria causing severe acute kidney injury.Am. J. Kidney Dis.201770686987310.1053/j.ajkd.2017.05.01328669550
     [Google Scholar]
  43. SimsekM. de BoerN.K.H. Mesalazine and nephrolithiasis: Leave no stone unturned.Am. J. Gastroenterol.201911481359136010.14309/ajg.000000000000031131261253
     [Google Scholar]
  44. YamamotoY. KurokawaY. OkaN. TakahasiM. FukumoriT. ShiraneY. KanayamaH.O. KagawaS.A. Pediatric case of ammonium acid urate lithiasis with ulcerative colitis.Nihon Hinyokika Gakkai Zasshi200293565265510.5980/jpnjurol1989.93.652
     [Google Scholar]
  45. JoyH.M. FairhurstJ.J. BeattieM.R. Renal calculus at presentation in a child with Crohn’s disease.Pediatr. Radiol.200333425025210.1007/s00247‑002‑0819‑z12709754
     [Google Scholar]
  46. RussinkoP.J. AgarwalS. ChoiM.J. KeltyP.J. Obstructive nephropathy secondary to sulfasalazine calculi.Urology200362474810.1016/S0090‑4295(03)00666‑614550462
     [Google Scholar]
  47. FujiiT. ShibaM. TakateraH. A case of ammonium urate urolithiasis with Crohn’s disease.Hinyokika Kiyo20034910615617
     [Google Scholar]
  48. HasanM.N. TiseliusH.G. Mesalamine: A rare constituent of urinary tract concretions.Urolithiasis201341327127210.1007/s00240‑013‑0553‑z23546224
     [Google Scholar]
  49. CorberyB. LebdaiS. BorojeniS. BigotP. AzzouziA.R. CultyT. Mesalazine: A novel etiology for drug-induced urinary calculi.Urol. J.201815313213310.22037/uj.v0i0.390229277882
     [Google Scholar]
  50. OgawaK. SakaguchiK. OkaS. NagamotoS. KurosawaK. UrakamiS. OkaneyaT. Drug-induced bilateral nephrolithiasis in an ulcerative colitis patient: A case report.J. Jpn Soc. Chem. Res.20191101414610.5980/jpnjurol.110.41
     [Google Scholar]
  51. VílchezA. OrtsJ.A. FrédériqueS.S. BenaventG. Mesalazine renal lithiasis.Arch. Esp. Urol.2020736561564
     [Google Scholar]
  52. PathanS.A. MitraB. StraneyL.D. AfzalM.S. AnjumS. ShuklaD. MorleyK. HilliS.A.A. RumaihiK.A. ThomasS.H. CameronP.A. Delivering safe and effective analgesia for management of renal colic in the emergency department: A double-blind, multigroup, randomised controlled trial.Lancet2016387100321999200710.1016/S0140‑6736(16)00652‑826993881
     [Google Scholar]
  53. PathanS.A. MitraB. CameronP.A. A systematic review and meta-analysis comparing the efficacy of nonsteroidal anti-inflammatory drugs, opioids, and paracetamol in the treatment of acute renal colic.Eur. Urol.201873458359510.1016/j.eururo.2017.11.00129174580
     [Google Scholar]
  54. SafaieA. TavoliM. BabaniamansourS. AliniagerdroudbariE. MousaviA. SotoodehniaM. BahreiniM. Intravenous morphine plus ibuprofen or ketorolac versus intravenous morphine alone in reducing renal colic pain intensity in emergency department.Turk. J. Emerg. Med.202222181410.4103/2452‑2473.33610835284698
     [Google Scholar]
  55. ForouzanfarM.M. MohammadiK. HashemiB. SafariS. Comparison of intravenous ibuprofen with intravenous ketorolac in renal colic pain management; A clinical trial.Anesth. Pain Med2019In Press, e8696310.5812/aapm.8696330881914
     [Google Scholar]
  56. SchmidtM. SørensenH.T. PedersenL. Diclofenac use and cardiovascular risks: Series of nationwide cohort studies.BMJ2018362k342610.1136/bmj.k342630181258
     [Google Scholar]
  57. BhalaN. EmbersonJ. MerhiA. AbramsonS. ArberN. BaronJ.A. BombardierC. CannonC. FarkouhM.E. FitzGeraldG.A. GossP. HallsH. HawkE. HawkeyC. HennekensC. HochbergM. HollandL.E. KearneyP.M. LaineL. LanasA. LanceP. LaupacisA. OatesJ. PatronoC. SchnitzerT.J. SolomonS. TugwellP. WilsonK. WittesJ. BaigentC. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials.Lancet2013382989476977910.1016/S0140‑6736(13)60900‑923726390
     [Google Scholar]
  58. GuercioS. AmbuA. MangioneF. MariM. VaccaF. BellinaM. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department.J. Endourol.20112571137114110.1089/end.2010.055421682597
     [Google Scholar]
  59. YallappaS. AmerT. JonesP. GrecoF. TaillyT. SomaniB.K. Umez-EroniniN. AboumarzoukO.M. Natural history of conservatively managed ureteral stones: Analysis of 6600 patients.J. Endourol.201832537137910.1089/end.2017.084829482379
     [Google Scholar]
  60. SkolarikosA. LagunaM.P. AlivizatosG. KuralA.R. de la RosetteJ.J.M.C.H. The role for active monitoring in urinary stones: A systematic review.J. Endourol.201024692393010.1089/end.2009.067020482232
     [Google Scholar]
  61. ShahT.T. GaoC. PetersM. ManningT. CashmanS. NambiarA. CumberbatchM. LambB. PeacockA. Van SonM.J. van RossumP.S.N. PickardR. ErotocritouP. SmithD. KasivisvanathanV. Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: Results from the Multi‐centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute ureteric Colic (MIMIC) study.BJU Int.2019124350451310.1111/bju.1477731001912
     [Google Scholar]
  62. DellabellaM. MilaneseG. MuzzonigroG. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi.J. Urol.2005174116717210.1097/01.ju.0000161600.54732.8615947613
     [Google Scholar]
  63. BorghiL. MeschiT. AmatoF. NovariniA. GianniniA. QuarantelliC. MineoF. Nifedipine and methylprednisolone in facilitating ureteral stone passage: A randomized, double-blind, placebo-controlled study.J. Urol.199415241095109810.1016/S0022‑5347(17)32511‑98072071
     [Google Scholar]
  64. PorpigliaF. DestefanisP. FioriC. FontanaD. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones.Urology200056457958210.1016/S0090‑4295(00)00732‑911018608
     [Google Scholar]
  65. DellabellaM. MilaneseG. MuzzonigroG. Medical-expulsive therapy for distal ureterolithiasis: Randomized prospective study on role of corticosteroids used in combination with tamsulosin—simplified treatment regimen and health-related quality of life.Urology200566471271510.1016/j.urology.2005.04.05516230122
     [Google Scholar]
  66. PickardR. StarrK. MacLennanG. LamT. ThomasR. BurrJ. McPhersonG. McDonaldA. AnsonK. N’DowJ. BurgessN. ClarkT. KilonzoM. GilliesK. ShearerK. BoachieC. CameronS. NorrieJ. McClintonS. Medical expulsive therapy in adults with ureteric colic: A multicentre, randomised, placebo-controlled trial.Lancet2015386999134134910.1016/S0140‑6736(15)60933‑325998582
     [Google Scholar]
  67. FurykJ.S. ChuK. BanksC. GreensladeJ. KeijzersG. ThomO. TorpieT. DuxC. NarulaR. Distal ureteric stones and tamsulosin: A double-blind, placebo-controlled, randomized, multicenter trial.Ann. Emerg. Med.20166718695.e210.1016/j.annemergmed.2015.06.00126194935
     [Google Scholar]
  68. SurR.L. ShoreN. L’EsperanceJ. KnudsenB. GuptaM. OlsenS. ShahO. Silodosin to facilitate passage of ureteral stones: A multi-institutional, randomized, double-blinded, placebo-controlled trial.Eur. Urol.201567595996410.1016/j.eururo.2014.10.04925465978
     [Google Scholar]
  69. TürkC. KnollT. SeitzC. SkolarikosA. ChappleC. McClintonS. Medical expulsive therapy for ureterolithiasis: The EAU recommendations in 2016.Eur. Urol.201771450450710.1016/j.eururo.2016.07.02427506951
     [Google Scholar]
  70. YeZ. ZengG. YangH. TangK. ZhangX. LiH. LiW. WuZ. ChenL. ChenX. LiuX. DengY. PanT. XingJ. WangS. ChengY. GuX. GaoW. YangJ. ZhangY. MiQ. QiL. LiJ. HuW. LiangP. SunZ. XuC. LongY. LiaoY. LiuS. LiuG. XuX. HeW. ChenZ. XuH. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: A multicenter, randomized, double-blind, placebo-controlled trial.Eur. Urol.201873338539110.1016/j.eururo.2017.10.03329137830
     [Google Scholar]
  71. OngA. BrownG. TokasT. HameedB.M.Z. PhilipJ. SomaniB.K. Selection and outcomes for dissolution therapy in uric acid stones: A systematic review of literature.Curr. Urol. Rep.202324835536310.1007/s11934‑023‑01164‑737079196
     [Google Scholar]
  72. El-GamalO. El-BendaryM. RagabM. RasheedM. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi.Urol. Res.201240321922410.1007/s00240‑011‑0406‑621858663
     [Google Scholar]
  73. SkolarikosA. MitsogiannisH. DeliveliotisC. Indications, prediction of success and methods to improve outcome of shock wave lithotripsy of renal and upper ureteral calculi.Arch. Ital. Urol. Androl.2010821566320593724
     [Google Scholar]
  74. PremingerG.M. TiseliusH.G. AssimosD.G. AlkenP. BuckA.C. GallucciM. KnollT. LingemanJ.E. NakadaS.Y. PearleM.S. SaricaK. TürkC. WolfJ.S. European association of urology. 2007 guideline for the management of ureteral calculi.Eur. Urol.20075261610163110.1016/j.eururo.2007.09.03918074433
     [Google Scholar]
  75. LaiS. JiaoB. DiaoT. SeeryS. HuM. WangM. HouH. WangJ. ZhangG. LiuM. Optimal management of large proximal ureteral stones (>10 mm): A systematic review and meta-analysis of 12 randomized controlled trials.Int. J. Surg.20208020521710.1016/j.ijsu.2020.06.02532622059
     [Google Scholar]
  76. PengC.X. LouY.K. XuL. WuG.H. ZhouX.L. WangK.E. YeC.H. Efficacy of emergency extracorporeal shock wave lithotripsy in the treatment of ureteral stones: A meta-analysis.BMC Urol.20232315610.1186/s12894‑023‑01226‑537016405
     [Google Scholar]
  77. AlsawiM. NalagatlaS. AhmadN. ChandiramaniA.S. MokoolL. NalagatlaS.K. SomaniB. AboumarzoukO.M. AmerT. Primary versus delayed ureteroscopy for ureteric stones: A systematic review and meta-analysis.J. Clin. Urol.202417548950310.1177/20514158221088687
     [Google Scholar]
  78. TzelvesL. GeraghtyR. MourmourisP. ChatzikrachtisN. KaravitakisM. SomaniB. SkolarikosA. Shockwave lithotripsy complications according to modified clavien-dindo grading system. A systematic review and meta-regression analysis in a sample of 115 randomized controlled trials.Eur. Urol. Focus2022851452146010.1016/j.euf.2021.11.00234848163
     [Google Scholar]
  79. WangW. PengL. DiX. GaoX. WeiX. Does previous unsuccessful shockwave lithotripsy influence the outcomes of ureteroscopy?—a systematic review and meta-analysis.Transl. Androl. Urol.20211052122213210.21037/tau‑21‑3934159093
     [Google Scholar]
  80. DrakeT. GrivasN. DabestaniS. KnollT. LamT. MaclennanS. PetrikA. SkolarikosA. StraubM. TuerkC. YuanC.Y. SaricaK. What are the benefits and harms of ureteroscopy compared with shock-wave lithotripsy in the treatment of upper ureteral stones? A systematic review.Eur. Urol.201772577278610.1016/j.eururo.2017.04.01628456350
     [Google Scholar]
  81. DasguptaR. CameronS. AucottL. MacLennanG. ThomasR.E. KilonzoM.M. LamT.B.L. N’DowJ. NorrieJ. AnsonK. BurgessN. ClarkC.T. KeeleyF.X. MacLennanS.J. StarrK. McClintonS. Shockwave lithotripsy versus ureteroscopic treatment as therapeutic interventions for stones of the ureter (TISU): A multicentre randomised controlled non-inferiority trial.Eur. Urol.2021801465410.1016/j.eururo.2021.02.04433810921
     [Google Scholar]
  82. GülerY. Non-contrast computed tomography-based factors in predicting ESWL success: A systematic review and meta-analysis.Prog. Urol.2023331274710.1016/j.purol.2022.09.01536202729
     [Google Scholar]
  83. LópezM. HoppeB. History, epidemiology and regional diversities of urolithiasis.Pediatr. Nephrol.2010251495910.1007/s00467‑008‑0960‑521476230
     [Google Scholar]
  84. ReynoldsT.M. ACP best practice no 181: Chemical pathology clinical investigation and management of nephrolithiasis.J. Clin. Pathol.200558213414010.1136/jcp.2004.01958815677531
     [Google Scholar]
  85. CirilloM. IudiciM. MarcarelliF. LaudatoM. ZinconeF. Nephrolithiasis in patients with intestinal diseases.G. Ital. Nefrol.20082514248
     [Google Scholar]
  86. FinkH.A. AkornorJ.W. GarimellaP.S. MacDonaldR. CuttingA. RutksI.R. MongaM. WiltT.J. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: A systematic review and meta-analysis of randomized trials.Eur. Urol.2009561728010.1016/j.eururo.2009.03.03119321253
     [Google Scholar]
  87. RodgersA.L. Allie-HamdulayS. JacksonG.E. SuttonR.A.L. Enteric hyperoxaluria secondary to small bowel resection: Use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols.J. Endourol.201428898599410.1089/end.2014.007724773381
     [Google Scholar]
  88. HoppeB. LeumannE. von UnruhG. LaubeN. HesseA. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria.Front. Biosci.200385113510.2741/113512957811
     [Google Scholar]
  89. İbisM.A. OktarA. GokceM.I. Dietary advice for patients with bowel-related conditions and malabsorption.World J. Urol.20234151235124210.1007/s00345‑023‑04281‑736648528
     [Google Scholar]
  90. AlonU.S. Medical treatment of pediatric urolithiasis.Pediatr. Nephrol.200924112129213510.1007/s00467‑007‑0740‑718273648
     [Google Scholar]
  91. MukewarS. HallP. LashnerB.A. LopezR. KiranR.P. ShenB. Risk factors for nephrolithiasis in patients with ileal pouches.J. Crohn’s Colitis201371707810.1016/j.crohns.2012.05.00622728147
     [Google Scholar]
  92. LieskeJ.C. GoldfarbD.S. De SimoneC. RegnierC. Use of a probioitic to decrease enteric hyperoxaluria.Kidney Int.20056831244124910.1111/j.1523‑1755.2005.00520.x16105057
     [Google Scholar]
  93. PremakumarY. GadiyarN. HameedB.M.Z. VenezianoD. SomaniB.K. Association of kidney stone disease (KSD) with primary gastrointestinal surgery: A systematic review over last 2 decades.Curr. Urol. Rep.20212263410.1007/s11934‑021‑01046‑w34027628
     [Google Scholar]
  94. IshiiG. NakajimaK. TanakaN. HaraH. KatoM. IshiiN. Clinical evaluation of urolithiasis in Crohn’s disease.Int. J. Urol.200916547748010.1111/j.1442‑2042.2009.02285.x19341366
     [Google Scholar]
  95. HuangV. MishraR. ThanabalanR. NguyenG.C. Patient awareness of extraintestinal manifestations of inflammatory bowel disease.J. Crohn’s Colitis201378e318e32410.1016/j.crohns.2012.11.00823265763
     [Google Scholar]
  96. CullenG. DonnellanF. LongS. ForryM. MurrayF.E. Perceptions of medication safety among patients with inflammatory bowel disease.Scand. J. Gastroenterol.20104591076108310.3109/00365521.2010.49059520459367
     [Google Scholar]
  97. JonesS.C. GallacherB. LoboA.J. AxonA.T.R. A patient knowledge questionnaire in inflammatory bowel disease.J. Clin. Gastroenterol.1993171212410.1097/00004836‑199307000‑000078409293
     [Google Scholar]
  98. EadenJ.A. AbramsK. MayberryJ.F. The Crohn’s and colitis knowledge score: A test for measuring patient knowledge in inflammatory bowel disease.Am. J. Gastroenterol.199994123560356610.1111/j.1572‑0241.1999.01536.x10606319
     [Google Scholar]
  99. SubasingheD. WijekoonN.S. NawarathneN.M. SamarasekeraD.N. Disease-related knowledge in inflammatory bowel disease: Experience of a tertiary care centre in a developing country in South Asia.Singapore Med. J.201051648448920658108
     [Google Scholar]
  100. MoradkhaniA. KerwinL. Dudley-BrownS. TabibianJ.H. Disease-specific knowledge, coping, and adherence in patients with inflammatory bowel disease.Dig. Dis. Sci.201156102972297710.1007/s10620‑011‑1714‑y21538016
     [Google Scholar]
/content/journals/cset/10.2174/0122102981375859250512064438
Loading
A Relationship between Inflammatory Bowel Diseases and Urinary Lithiasis
Curr. Sci. Eng. Tech. 5, 37 (2025); https://doi.org/10.2174/0122102981375859250512064438
/content/journals/cset/10.2174/0122102981375859250512064438
/content/journals/cset/10.2174/0122102981375859250512064438
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): crohn's disease; Inflammatory bowel disease; risk factors; ulcerative colitis; urinary stones; urolithiasis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test